FDA calendar · October 2023 · built from SEC filings

PDUFA dates October 2023: FDA calendar and catalysts.

Updated Snapshot 20261116T222116ZBuilt

0 PDUFA dates fell in October 2023. The FDA calendar also recorded 40 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

PDUFA dates in October 2023

No PDUFA dates are disclosed for this period as of November 16, 2026.

Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months

October 2023: other FDA decisions and filings

DateDrugCompanyEventIndicationStatusSource
Oct 2023Month disclosedONPATTRO® (patisiran)ALNYComplete Response Letter—CRL issuedSEC Form 10-Q
Oct 2023Month disclosed—ALVOComplete Response Letter—CRL issuedsec_424b
Oct 2023Month disclosedChenodalMIRMNDA/BLA submission—CompletedSEC Form 10-Q
October 4, 2023Abrilada (adalimumab-afzb)PFELabel expansion—ApprovedopenFDA Drugs@FDA
October 5, 2023LUMYKRAS™ (sotorasib)AMGNAdvisory committee—NegativeFDA advisory committee calendar
October 5, 2023ZORYVE (roflumilast)ARQTLabel expansionplaque psoriasisApprovedSEC Form 10-Q
October 6, 2023Cosentyx (secukinumab)NVSFDA approval—ApprovedopenFDA Drugs@FDA
October 11, 2023Selarsdi (ustekinumab-aekn)ALVOComplete Response Letter—CRL issuedFDA Complete Response Letters
October 12, 2023KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
October 12, 2023Velsipity (etrasimod arginine)PFEFDA approvalTo treat moderately to severely active ulcerative colitis in adultsApprovedFDA Novel Drug Approvals
October 13, 2023Opdivo® (nivolumab)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
October 17, 2023XPHOZAH® (tenapanor)ARDXFDA approval—ApprovedSEC Form 10-K
October 23, 2023—IBRXComplete Response Letter—CRL issuedsec_424b
October 23, 2023KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
October 23, 2023Multaq (dronedarone hydrochloride)SNYLabel expansion—ApprovedopenFDA Drugs@FDA
October 26, 2023—IBRXNDA/BLA accepted—Completedsec_424b
October 26, 2023Omvoh (mirikizumab-mrkz)LLYFDA approvalTo treat ulcerative colitisApprovedFDA Novel Drug Approvals
October 27, 2023LOQTORZI (toripalimab)CHRSFDA approvalwith recurrent, unresectable, or metastatic NPC with disease progressionApprovedSEC 8-K Exhibit 99.1
October 27, 2023Loqtorzi (toripalimab-tpzi)CHRSFDA approval—ApprovedFDA Novel Drug Approvals
October 30, 2023Orencia (abatacept)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
October 31, 2023Wezlana (ustekinumab-auub)AMGNFDA approval—ApprovedopenFDA Drugs@FDA
October 31, 2023Cosentyx (secukinumab)NVSLabel expansion—ApprovedopenFDA Drugs@FDA
October 31, 2023exagamglogene autotemcel (CTX001)VRTXAdvisory committee—CompletedFDA advisory committee calendar

October 2023: dated readouts

DateDrugCompanyEventIndicationStatusSource
Oct 2023Month disclosedChenodalMIRMTopline readout—PositiveSEC Form 10-Q
Oct 2023Month disclosed—MLTXTopline readoutmoderate-to-severe HSPositiveSEC Form 10-Q
Oct 2023Month disclosed—QUCYTopline readout—Positivesec_424b
October 9, 2023vidofludimusIMUXInterim readout—Positivesec_424b
October 30, 2023brilaroxazineRVPHTopline readoutschizophreniaPositivesec_424b
October 30, 2023—RVPHTopline readout—Positivesec_424b
October 31, 2023HLP003HELPInterim readoutmoderate to severe MDDMet primary endpointSEC 8-K Exhibit 99.1
October 31, 2023CYB003HELPInterim readoutmoderate to severe MDDMet primary endpointSEC 8-K Exhibit 99.1

October 2023: trial starts and primary completions

DateDrugCompanyEventIndicationStatusSource
Oct 2023Month disclosedELI-002ELTXTrial start—CompletedSEC Form 10-Q
Oct 2023Month disclosedrezpegaldesleukin (NKTR-358)NKTRTrial startmoderate-to-severe atopic dermatitisCompletedSEC Form 10-Q
Oct 2023Month disclosedISEMBYLD (apitegromab)SRRKTrial start—CompletedSEC Form 10-Q
Oct 2023Month disclosedTARA-002TARATrial startmacrocystic and mixed-cystic LMsCompletedSEC Form 10-K
Oct 2023Month disclosedBDC-3042BOLTTrial startbroad range of solid tumorsCompletedSEC Form 10-Q
Oct 2023Month disclosedDT-216DSGNTrial start—CompletedSEC Form 10-Q
Oct 2023Month disclosedDISC-3405IRONTrial start—CompletedSEC Form 10-Q
Oct 2023Month disclosedefzofitimod (ATYR1923)ATYRTrial start—Completedsec_424b
Oct 2023Month disclosedFIT-001KURATrial start—CompletedSEC Form 10-K

Questions

What PDUFA dates are in October 2023?

0 PDUFA dates fell in October 2023. The FDA calendar also recorded 40 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

Can these dates change?

Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.